Patents by Inventor Mohamed ElSayed Hamed Elsayed

Mohamed ElSayed Hamed Elsayed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP/GLP1 co-agonist compounds
    Patent number: 12252524
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: March 18, 2025
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Andrew Brown, Mohamed ElSayed Hamed ElSayed, Hongchang Qu, Huyen Thanh Tran, Aktham Aburub, Phenil Jayantilal Patel
  • GIP/GLP1 co-agonist compounds
    Patent number: 11084861
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 10, 2021
    Assignee: Eli Lilly and Company
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20200024322
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Kyle Wynn Sloop, Francis Stafford Willard, Thi Thanh Huyen Tran, Aktham Aburub, Phenil Jayantilal Patel, Amita Datta-Mannan, Xianyin Lai